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2Abstract.  Preparations of arachidonic acid binding and non-binding proteins from bovine brain,
four acidic proteins ("-casein, phosvitin, $-lactoglobulin A and B), the peptide polyglutamate,
and  two polyanions (heparin, dextran sulfate) enhanced both basal and glucose 6-phosphate
induced solubilization of rat brain mitochondrial hexokinase (ATP:D-hexose 6-
phosphotransferase, EC 2.7.1.1).  In contrast, three other acidic proteins, had  little ("-
lactalbumin) or no effect (bovine serum albumin, ovalbumin) and five basic proteins inhibited
release of the enzyme.   Solubilizing activity therefore appears to require a net negative charge
and one or more of the following structural features: extended conformation, random coil,
unordered or $-structure, in this case the $-barrel in the fatty acid binding proteins and $-
lactoglobulins. It is of interest that a difference of a single negative charge between $-
lactoglobulin A and B, resulted in a statistically significant difference in the stimulation of
hexokinase release.  Possible physiological and pathological roles of this solubilizing effect are
discussed briefly. 
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3Introduction
Hexokinase (HK) type 1 (e.g. Abrain hexokinase@) binds to the hexokinase binding protein
(Felgner et al.1979), aka mitochondrial porin (Fiek et al.1982, Linden et al.1982, reviews by
Wilson 1995, 2003), in the outer mitochondrial membrane.  The enzyme can be solubilized from
this site by, most importantly, G6P and ATP (Rose and Warms 1967, Wilson 1968, 1980).  Since
the soluble form is less active than the bound form (Wilson 1978, 1980) it has been suggested
that the solubilization by G6P and the counteraction of this, particularly by inorganic phosphate
(Rose and Warms 1967, Wilson 1968), may exert metabolic control of the enzyme in the brain
and some other tissues.   Mg2+ at low, millimolar concentrations similarly inhibits solubilization
by G6P possibly via screening of repulsive negative charges on the enzyme and the
mitochondrion (Felgner and Wilson 1977, Wilson 1980).  Type 2 HK (insulin- inducible
hexokinase) also binds to the mitochondrion and behaves in a similar, although not identical,
manner in insulin sensitive tissues (Wilson 1995, 2003).  The importance of the above type of
control depends, in part, clearly on the extent to which the enzyme can be solubilized by G6P and
this has been found to vary in different species (Kabir and Wilson 1993, 1994).  In the context of
this paper it is of further interest that the soluble, but not the bound, form of the enzyme is
susceptible to proteolytic breakdown (Crinelli et al. 1997, Polakis and Wilson 1985).  
More recently an important mechanism of control of this enzyme has been shown to involve
coupling of glucose phosphorylation by the bound hexokinase to oxidative phosphorylation
(BeltrandelRio and Wilson 1991, 1992, De Cerquiera and Wilson 1995, 1998, Laterveer et al.
1995, 1997, Wicker et al.1993).  There is evidence that this mechanism involves a mitochondrial
porin as well as adenine nucleotide translocase (Beutner et al. 1996).                                           
4In view of the above it was of interest when it was found that preparations of rat liver and brain 
fatty acid binding proteins (FABPs) enhanced basal and G6P- stimulated release of hexokinase
from rat brain mitochondria (see Results).   The present paper deals with the solubilization of
mitochondrial HK by some arachidonic acid binding proteins and some other acidic proteins and 
macromolecular polyanions.
   Materials and methods. 
Materials.  Rat liver and brain FABPs were prepared using brains from 300g male Sprague
Dawley rats. Bovine brains were obtained from healthy heifers at slaughter. The bovine brains
were placed in ice within 15 minutes of slaughter of the animals.  Enzymes (snake venom
phosphodiesterase (PDE, orthophosphoric diesterphosphohydrolase, EC 3.1.4.1), turkey egg
white lysozyme (muramidase, mucopeptide N-acetyl- muramoylhydrolase, EC 3.2.1.17),
micrococcal nuclease from Staphylococcus aureous (micrococcal endonuclease, EC 3.1.31.1),
RNase (ribonuclease A, ribonucleate 3'-pyrimidinooligo-nucleotidohydrolase EC 3.1.27.5)) and
other proteins, coenzymes, and Sephacryl S-100 HR were from Sigma Chemical Company, St.
Louis, Missouri.  Additional chromatography media were from Pharmacia Canada, Dorval,
Quebec.  Ultrafiltration membranes and Centricon 3 Microconcentrators were from Amicon
Canada, Oakville, Ontario. Arachidonic acid [5,6,8,9,11,12,14,15-3H(N)] was obtained from
NEN Research Products, Boston, Massachusetts. 
Preparations.  All procedures were carried out at or  below 5EC and preparations, at any stage,
were stored at - 20EC (e.g. brain cytosol fractions) or in liquid nitrogen (minced grey matter).
Ethylene glycol was added to some preparations to a concentration of 15 % (v/v).  Highly
purified rat liver and brain FABP were prepared by classical methods (Ockner et al. 1982). 
5Bovine brain cytosol fraction was obtained by homogenization of minced grey matter in three
volumes of buffer (0.32 M sucrose, 5mM Tris-HCl, 1mM EGTA, 0.85 mM PMSF, pH 7.4) and
ultracentrifugation.  Using a PM-10 ultrafilter the cytosol fraction was concentrated and the
concentrate separated on a short column of Sephacryl S-100 HR (referred to as Sephacryl
Column1 in the following) with buffer AA@ (10 mM Tris-HCl, 0.15 M NaCl, pH 7.4). This
separation produced the elution profile shown  in Fig. 1A (see figure for further details).  The
fractions appearing in the cytochrome c position (the “shoulder” of the descending limb of the
elution profile) were pooled (“Peak”A1 in the following) and, after concentration, and addition of
arachidonic acid [5,6,8,9,11,12,14,15-3H(N)], the concentrate was rechromatographed on a long
column of Sephacryl S-100 HR (referred to as Sephacryl Column 2 below)  using buffer AA@ (see
Fig. 1B for details).  The high molecular weight, radiolabelled material in “Peak”B1 from this
column (Fig. 1B) was not further studied (it may contain aggregated fatty acid binding proteins
(Fournier et al. 1983)).  The radiolabelled fractions from the cytochrome c position on the other
hand were combined (Peak B2, see Fig. 1B) and after concentration on an Amicon PM-10
ultrafilter, and exchange of the buffer with buffer AB@  (30 mM Tris-HCl, 15% ethylene glycol
vol/vol, pH 8.5) placed on a DEAE Sepharose column.  The DEAE column was next eluted with
buffer AB@ followed by a 0-0.25M NaCl gradient in this buffer (see Fig. 2 for details).  The
fractions appearing in the cytidine position on Sephacryl Column 1 (combined in Peak A2, see
Fig.1 A) were concentrated (Amicon YM-2 membrane) and rechromatographed on a long
column of Sephacryl S-100 R (Sephacryl Column 3, Fig. 3) but without labelling with
arachidonic acid.  Only the higher molecular weight fractions of “Peak 1" from the latter column
contained protein as determined by the Lowry assay (see Fig. 3 for details).  All major peaks
6from the DEAE column, and some of the pooled fractions (“Peaks”) from the three Sephacryl
columns, were assayed for HK-releasing activity (see Table 1 below).  Assays.  The buffer in all
preparations assayed for activity was exchanged with Hepes buffer (20mM Hepes, 15% ethylene
glycol (vol/vol) pH 7.0) in order to eliminate effects of increased concentrations of salts on HK
release (Felgner and Wilson 1977).  Commercial protein/peptide preparations and heparin and
dextran sulfate were dissolved in, and dialyzed against 10mM Hepes, pH 7.0 or transferred to
this buffer using Centricon 3 microconcentrators.  Rat brain mitochondria were prepared as
described by Moller and Wilson (1983).  Basal and G6P-stimulated release of the mitochondrial
hexokinase were as described by Moller and Wilson (1983).  Total HK activity (i.e. solubilized
plus remaining bound, including latent activity released by 0.5% Triton X-100) was also
determined.  The average mitochondrial protein concentration in these assays, determined by the
Biuret assay (Gornall et al. 1949), was 0.9 "0.08 mg/mL, n=13.  Other protein determinations
were carried out by the Lowry assay (Lowry et al. 1951). Electrophoresis under denaturing
conditions was as described by Laemmli (1970).  Student’s t-test was used to determine
significance of differences when possible.
Results
Preliminary experiments showed that  rat liver FABP (single band by electrophoresis) at 2.5 mg
per mL doubled basal HK release and increased G6P-stimulated release 41% (n=5, p<0.05 and
p<0.001 respectively by paired variate analysis).  Furthermore rat brain FABP in one experiment
tripled basal and doubled G6P-stimulated HK release.  Two other smaller rat brain proteins,
obtained in very small amounts, similarly increased HK release (results not shown).                
The DEAE column chromatography (Column 3) of bovine brain preparations resulted in three
7major (i.e. “Peaks@ 4, 5,and 8), and several minor, arachidonic acid labelled peaks as well as
three major unlabelled peaks  (“Peaks” 2, 6, and 7, see Fig. 2 for details).  It may be noted at this
point that Schoentgen et al. (1989) found microheterogeneity in FABP purified from bovine
brain.  All these preparations caused release of HK whether they bound arachidonic acid or not
thus suggesting a nonspecific, likely charge related, effect (Table 1).  Both basal and G6P-
stimulated release were enhanced by these preparations except when basal release appeared to be
maximally stimulated as in the two cases of preparations from Peak 2, Column 1 (see Table 1). 
Hexokinase activity per se was also slightly increased in the presence of G6P by these particular
preparations as shown by increases of total activity over controls (Table 1, and  results not
shown).  In contrast, HK activity was not affected by the other bovine brain preparations as
suggested by recoveries (total activities) close to 100% of controls (see Table 1).  That fatty acid
binding by some of these proteins was not involved in solubilizing the enzyme was suggested by
the finding that treatment of rat liver FABP and protein in peak 2 from column 2 (see Fig.1 B)
with Lipidex 1000 to remove bound fatty acids (Glatz and Veerkamp 1983) was without effect
on their HK-releasing activity (results not shown).  HK-releasing activity was independent of
elution position on the DEAE column and thus apparently also of differences of (net negative)
charge on the proteins.  
Hexokinase releasing activity of other proteins and some polyanions.  Since it was possible,
given these data, that the HK-releasing activity was restricted to proteins with a net negative
charge some polyanions and some proteins with either a net negative or positive charge at pH 7
were examined next for activity.  Table 2 shows that the polyanions heparin and dextran sulfate,
both with a high negative charge density, as well as the highly negatively charged peptide
8polyglutamate had high activity.  Additionally, heparin and dextran sulphate also inhibited the
hexokinase as shown by lower total activities (recoveries) than the controls.  Presumably the
sulfate groups were responsible for this inhibition since no inhibition was noted in the presence
of compounds carrying only carboxylate groups or carboxylate and phosphate groups.  The
activity of some other (net) negatively charged, but less so, proteins (Table 3) varied from
moderate (the phosphoproteins "-casein, and phosvitin, as well as the $-lactoglobulins) to low
("-lactalbumin) or virtually non- existent (BSA, and ovalbumin).  
In contrast all five positively charged (at pH 7) proteins tested, except apparently snake venom
phosphodiesterase, inhibited basal HK release and all five, without exception, inhibited release in
the presence of G6P (Table 4).  The apparent increase of basal release by the phosphodiesterase
(Table 4) was most likely due to lysis of the mitochondria with concomitant solubilization of
proteins, including hexokinase.  All five positively charged proteins caused agglutination of the
mitochondria, but only the phosphodiesterase caused lysis (results not shown).
         Discussion
Since not all the negatively charged proteins tested increased the release of the hexokinase and
since positively charged proteins were inhibitory in this regard (possibly due to occlusion of the
agglutinated mitochondria, however) it is concluded that a net negative charge is a necessary, but
not sufficient, condition for HK-releasing activity of a protein. Thus certain structural features
appear also to be required.  Based on the structures of the proteins tested these would include:  A
random coil structure in aqueous solution as in polyglutamate (Iizuka and Yang 1965), open
flexible chains especially in phosphate carrying regions as in casein and phosvitin (Holt and
Sawyer 1988, Holt 1992)), and $-structure, especially the $-barrel as in the $-lactoglobulins
9(Papiz et al. 1986, Banaszak et al. 1994).  The "-casein (a mixture of 60% "s1 + "s0 casein and
40% $-casein with 8-9 and 5 mol P/ mol repectively arranged in clusters of two or four (Holt
1992)) had moderately high activity similar to polyglutamate.  Considering this the low activity
of phosvitin which has nearly enough phosphate groups to give a negative charge density of one
per amino acid residue (Taborsky 1983) was a surprise.  It is possible that this low activity is due
to aggregate formation of the protein during frozen storage  (Taborsky 1974).  Of great interest,
and needing further work, is the finding that the A form of $-lactoglobulin, which has just one
more negative charge (in the $-barrel) than the B form (Braunitzer et al. 1972), also is the most
active of the two (Table 2).  Significantly, the $-barrel is also a prominent structural feature of
the FABPs (Banaszak et al.1994).  This circumstance and the finding that the protein must have a
net negative charge add to the evidence that the FABPs indeed have this activity.  It would be of
interest to study the effect of phosphorylation on the activity of these proteins. The lack of
activity of BSA may be due to the "-helical and overall rigid tertiary structure, due to its many
disulfide bonds, of this negatively charged (at pH 7) protein (Brown 1976, Carter and Ho 1994). 
The virtual lack of activity of ovalbumin is at odds with the criteria outlined above.  This protein
has a high negative charge (see data of Nisbet et al. 1981) including two phosphate groups
(Vogel and Bridger 1982) and more than fifty percent $-structure (Stein et al. 1991).  The lack of
a $-barrel or, possibly, a diffuse distribution of its negative charges may perhaps explain its lack
of activity.  The (low) activity of "-lactalbumin may be due to its negative charge and fifty to
sixty percent unordered structure (B variant, McKenzie and White 1991).  Finally, both a high
negative charge density and extended conformation are characteristics of glycosaminoglycans
thus explaining the high activity of heparin and in a similar way of dextran sulfate.
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 Possible applications of the findings.  The low concentration of FABPs in the brain (Bass et al.
1984, Bass and Manning 1986) probably precludes any role in the control of the distribution and
activity of HK in brain tissue.  However, such control may be possible e.g. in the heart and in
skeletal muscle which have both a (constitutive) type 1 HK (Abrain HK@) and the insulin
inducible type 2 HK ( Wilson 1995, 2003).  As noted in the introduction both of these
hexokinase isozymes bind to the mitochondrion and are released by G6P.  By causing complete
solubilization or perhaps rather a switch from firm binding to porin to a more loose binding to
the enzyme via  Mg2+- Abridges@ FABPs could play a role in changing from glucose to fatty acid
oxidation in heart and muscle and some other tissues which have both isozymes.  Such a role
would dovetail well with the function of FABPs as delivery vehicles for fatty acids to the
mitochondrion (Fournier et al. 1978, Fournier and Rahim 1985).  
Given that a net negative charge and certain structural features may impart HK-releasing activity
to proteins and glycosaminoglycans (GAGs) pathological conditions may occur in the brain in
which this activity may come into play.  This may for example be the case with certain sulfated
glycosaminoglycans (GAGs).  Thus heparan sulfate (Snow et al. 1989, Goedert et al. 1996) and
other sulfated GAGs (Bonay and Avila 2001) may be present intraneuronally in the brain in
Alzheimer=s Disease (AD). It is of interest in this connection that various sulfated
glycosaminoglycans (Goedert et al. 1996 and Hasegawa et al. 1997) and polyanions like dextran
sulfate and RNA (Kampers et al.1996 and Hasegawa et al. 1997) stimulate hyperphosphorylation
and aggregation of tau proteins in vitro.  Furthermore, since a single addition of a negative charge
may increase the HK-releasing effect of a protein it is likely that addition of several negative
charges as in hyperphosphorylation would be even more effective in this respect.  Thus
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hyperphosphorylated, acidic, rodlike tau proteins (Cleveland et al. 1977) have been found
intracellularly in AD (Friedhoff et al. 2000, Köpke et al. 1993, Sato et al. 2001) and other
dementias with tau pathology (Goedert and Spillantini 2000, Delacourte and Buée 2000).  As a
result solubilization of the hexokinase could occur rendering the enzyme both less active (Wilson
1978, 1980) and subject to proteolytic breakdown (Polakis and Wilson 1985, Crinelli et al.1997). 
In addition as indicated in the introduction, and probably more important, coupling to oxidative
phosphorylation could be interrupted causing lack of control of glucose oxidation.  Supporting
these possibilities are findings that glucose metabolism is decreased in AD (Piert et al. 1996)
even when correction is made for atrophy of the brain (Alavi et al. 1993, Tanna et al.1991, Ibanez
et al. 1998).  Further support comes from findings that aggregated tau proteins besides being
enzymatically glycosylated are highly glycated,  i.e. nonenzymatically glycosylated (Ledesma et
al. 1994, Ledesma et al. 1995, Nacharaju et al. 1997) suggesting exposure to sustained high
levels of glucose.  Considering that the brain depends virtually completely on glucose for its
energy requirements a decreased rate of its metabolism may thus be a contributing factor in the
progression of AD and other dementias involving accumulation of hyperphosphylated proteins
such as the tau-proteins.  Recent studies have demonstrated an antiapoptotic effect of
mitochondrially bound hexokinases, i.e. either type 1 or type 2  (review: Pastorino and Hoek
2003, Azoulay-Zohar et al. 2004).  Release of the enzymes by the charge- related mechanism
outlined above could therefore lead to death of neurons in diseases such as AD and, in general, to
cell death in other tissues than the brain. 
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Table 1.  Solubilization of rat brain mitochondrial hexokinase activity                                            
                by bovine brain preparations.                                                                    
   Column /        Protein    Released Hexokinase              Total Hexokinase 
     Peak   mg/mL                   % of Control                        % of Control  
                                                   -G6P             +G6P              -G6P              +G6P      
   1 / 2                  3.0                  1325                84                  103                 118 
   1 / 2                  3.0                  1416              114                  107                 113      
   2 / 2                  1.5                    186              149                  100                   94    
   3 / 1                  1.5                    155              141                  100                   98     
   3 / 2                  1.5                    183              144                    96                 100     
   3 / 3                  1.5                    184              138                    97                 103      
   3 / 4                  1.5                    396              220                    98                   93      
   3 / 5                  1.5                    361              193                    96                   97       
   3 / 6                  1.5                    284              178                  104                 104      
   3 / 7                  1.5                    225              211                    96                 102      
   3 / 7                  3.0                    340              272                    96                 108      
   3 / 8                  1.5                    209              203                    97                 109      
   3 / 8                  3.0                    324              230                    95                 106
   4 / 1                  1.5                    491              310                      -                    -           
   4 / 1                  1.5                      -                 365                      -                    -         
                       
The results are from eight different experiments.  Mean hexokinase activities (units
per mL×10-4 ± SD) in the controls, i.e. without added brain preparation, were: 
Basal, 0.17±0.07; G6P-stimulated, 1.94± 0.48; total, 7.82±0.67.   Precision of                  
duplicate determinations (Colton 1974) using the results in Table 1 and measured                      
by the average standard deviation was ± 8.3 × 10-6  units/mL in the absence -and         
± 24.2 × 10-6 units/mL in the presence of G6P.   
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Table 2.  Solubilization of rat brain mitochondrial hexokinase by three 
                negatively charged polymers.                                         
Compound       Conc.            Released Hexokinase         Total Hexokinase
      / n              mg/mL                % of Control                     % of Control 
                                                       
                                              &G6P           %G6P            &G6P          %G6P
Heparin/4            3                  2086             213                 78               83
                                               p<0.01         p<0.001
Dex. Sulfate/3     3                  1856             213                 69               78
                                               p<0.01         p<0.05
Polyglutam./3     3                    512              260               100             105                      
                                               p<0.02         p<0.02
______________________________________________________________
The results are from 10 different experiments.  Average released activities
(units per mL × 10-4 ± SD) of controls were: Basal,  0.18 ±0.03; G6P-  
stimulated, 2.03 ± 0.24; total, 6.76 ±0.50.  The number of duplicate  
determinations is indicated by n, and p is the probability of the difference
between a results and its control being zero.  See Methods for further details.                                  
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Table 3.  Solubilization of rat brain mitochondrial hexokinase by 
                some acidic proteins (pI<7)a                                                                       
Compound        Conc.         Released Hexokinase            Total Hexokinase
       /n               mg/mL              % of Control                       % of Control      
                                                    
                                               &G6P          %G6P               &G6P         %G6P  
BSA     /1              1                    97                90                  112             103 
BSA     /1             3.75                90              102                    nd               nd
BSA     /1             15                 100              103                    nd               nd
"-casein /3             3                 430               259                    94             113
                                               p<0.01        p<0.001
"-lactalbumin /2    3                 132               135                    98             101
                                                p: nd             p: nd                                           
$-lactoglob. A /3    3                 307              173                    97              110
                                                p<0.02        p<0.01
$-lactoglob. B /3    3                 197               136                  100             107
                                                 p<0.01        p<0.01                                           
phosvitin /3            3                 300               173                   106            105             
                                                 p<0.02        p<0.02 
ovalbumin /2          3                  96                121                     97            102      
                                                 p: nd             p: nd                                           
a The difference between the stimulation of basal release by $-lactoglobulin A 
and B was significant at the 0.05 level and in the presence of of G6P at the 0.01
level.  See footnote to Table 2 and Methods for further details.                                     
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Table 4.  Effect of some basic proteins on release of mitochondrial hexokinase.
 Protein                    Conc.       Released Hexokinase            Total Hexokinase              pI Ref.      
                                mg/mL       % Control Activity             % Control Activity                          
 
   - G6P   + G6P    - G6P   + G6P
                 
                 
Cytochrome c    0.50      
   1.00
     112        
       44
     62         
     39
    115        
    105
    108         
    101
  10.7a     
Lysozyme    0.25      
   0.50
       61        
       32  
     50         
     23
     105       
       89
     102        
       87
  11.0a    
RNase    0.50      
   1.00
       98        
       52
     73         
     44
     106       
       99
     105        
     101
    9.7a     
Phospho-        
diesterase
   0.50      
   1.00
     220        
     142
     77         
     59
     119       
     117
     116        
     114
    9.0b      
Micrococcal   
Endonuclease
   0.25      
   0.50
       80        
       63
     50         
     38
     101       
     103 
     101        
       97
  10.4c       
            
 Average activities released (units per mL x 10-4) of controls were: basal, 0.325; G6P-
stimulated,  2.58; total, 10.83.  Isoelectric points cited in: a Kimelberg and Papahadjopoulos
(1971); b Dolapchiev et al. 1980; c calculated from amino acid sequence in: Taniuchi et al. 1967. 
See text for further details                                                                         
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Text to Figures
Fig. 1.  Fractionation of bovine brain cytosol fraction.  A.   Sephacryl Column 1.  Concentrated
cytosol fraction (684 mg protein in 11 mL) was applied to, and eluted on, a 5cm i x18 cm
column of Sephacryl S-100 HR with buffer A (see Methods).  The column was calibrated with a
mixture of Blue Dextran, BSA (not shown), cytochrome c, and cytidine.  “Peaks” 1 and 2
correspond to number of fractions of 7.1 mL indicated by the bars in the figure.  B.  Sephacryl
Column 2.  To the concentrated “Peak” 1 (10mL, 437 mg protein) , i.e. shoulder at cytochrome c
position, from column 1 was added tritium-labeled arachidonic acid (1 :Ci in 10 :L ethanol at
0° C) and the mixture eluted on a 2.5cm i x 95cm column of Sephacryl S-100 HR with buffer A. 
The column was calibrated as above.  “Peaks” 1 and 2 correspond to number of fractions (3.25
mL) pooled as indicated by the bars. 
Fig. 2. Column 3.  Concentrated  Peak 2, i.e. from cytochrome c position on column 2 (49 mg
protein in 16 mL), was transferred to buffer B and applied slowly to a column (1.6cm i x 30cm)
of DEAE Sepharose CL6B equilibrated with the same buffer (see Methods).  The column was
eluted with two bed volumes buffer B at which point a  NaCl gradient (0-0.25M) was 
superimposed and five more bed volumes collected.  Fractions of 2.8 mL were pooled (Peaks 1,
2, etc.) corresponding to the numbers above the peaks. 
Fig. 3.  Column 4.(Sephacryl Column 3)  Fractionation of “Peak 2" from Column 1 on Sephacryl
S-100 HR:  2.5 mg protein in 0.4mL, was applied to the column ( 0.92cm i x 125cm)
equilibrated and then eluted with buffer B.  Fractions of 0.56 mL were pooled (Peaks 1, 2, and
3) as indicated by the bars.
